Interactive Tools

Trending on OncLive

Osimertinib Plus Gefitinib Suppresses Acquired EGFR Resistance Mutations in First-Line NSCLC

FDA Grants Fast Track Designation to Cesalatamig in Immunotherapy-Pretreated NSCLC

AMIGO-1 Trial Meets 18-Month PFS End Point With Frontline Amivantamab Triplet in EGFR+ NSCLC

TUB-040 Elicits Clinically Meaningful Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer

Japan Approves T-DXd, Dato-DXd in Select First-Line Metastatic Breast Cancers Indications